pioglitazone has been researched along with alpha-Galactosidase A Deficiency in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lukas, J | 1 |
| Pockrandt, AM | 1 |
| Seemann, S | 1 |
| Sharif, M | 1 |
| Runge, F | 1 |
| Pohlers, S | 1 |
| Zheng, C | 1 |
| Gläser, A | 1 |
| Beller, M | 1 |
| Rolfs, A | 1 |
| Giese, AK | 1 |
1 other study available for pioglitazone and alpha-Galactosidase A Deficiency
| Article | Year |
|---|---|
Enzyme enhancers for the treatment of Fabry and Pompe disease.
Topics: 1-Deoxynojirimycin; Acetylcysteine; alpha-Galactosidase; alpha-Glucosidases; Ambroxol; Bezafibrate; | 2015 |